US Edition
News from endpoints.news
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top endpoints.news News
US Politics · United StatesPresident Donald Trump unveiled a deal with UK-based drugmaker AstraZeneca on Friday under which the company will sell some medicines at a discount to the government's Medicaid health plan in exchange for tariff relief, similar to a drug pricing pact reached last week with Pfizer.See the Story
Trump, AstraZeneca announce US drug pricing deal at White House
62% Center coverage: 146 sources
Wall Street · New BrunswickJ&J Chief Financial Officer Joseph Wolk explained that whilst DePuy Synthes is ‘still a great business’, it is not as fast-growing or as profitable as other core operationsSee the Story
J&J to Spin Off Orthopaedics Unit After Strong Q3 Results, Stock Falls 1%
42% Left coverage: 12 sources
Eli LillyBain Capital Private Equity led Kailera Therapeutics’ Series B financing, which will support global Phase 3 tests of KAI-9531, a weekly injectable drug that hits the same targets as Eli Lilly’s blockbuster obesity medication, Zepbound. The capital will also support development of other oral and injectable metabolic medicines in Kailera’s pipeline. The post Kailera Secures $600M to Advance Dual-Targeting Obesity Drug to Global Phase 3 Tests appea…See the Story
Kailera Secures $600M to Advance Dual-Targeting Obesity Drug to Global Phase 3 Tests
100% Center coverage: 2 sources
